Inactive Instrument

Press Releases OUTLOOK THERAPEUTICS, INC. Nasdaq

Equities

US69012T1079

Press Releases

Unlock all the news: Be the first to know and act before the market!

Corporate Presentation: June 2024	06-05	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	05-29	AQ
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	05-28	AQ
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	05-15	AQ
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	05-13	AQ
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	05-09	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	05-02	AQ
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	04-29	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	04-16	AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	04-15	AQ
Corporate Presentation: March 2024	03-28	PU
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-25	AQ
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-22	AQ
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	03-18	AQ
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split	03-13	AQ
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	03-12	AQ
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	02-15	AQ
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	02-14	AQ
Outlook Therapeutics® Doses First Subject in NORSE EIGHT	01-31	AQ
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010	01-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OUTLOOK THERAPEUTICS, INC. Nasdaq

Equities

US69012T1079

Press Releases

Filters